“NASHA was not superior to placebo for the primary efficacy analysis. However, these data may be confounded by the inclusion of patients with osteoarthritis at other sites, as significant benefits over placebo were found among patients with osteoarthritis confined to the knee. Future trials of osteoarthritis that examine a local therapy might need to consider restricting the study population to those patients having osteoarthritis of only the signal joint.”

Article complet disponible chez Elsevier.

“Single-injection NASHA was well tolerated and, although there was no significant benefit versus saline control in the primary analysis, post-hoc analysis showed a statistically significant improvement in pain relief at 6 weeks among patients without clinical effusion at baseline.”

Résumé de l’article disponible sur PubMed.gov.

 

“This study shows that single-injection NASHA was well tolerated and non-inferior to MPA [methylprednisolone acetate] at at 12 weeks. The benefit of NASHA was maintained to 26 weeks while that of MPA declined. An injection of NASHA at 26 weeks conferred long-term improvements without increased sensitivity or risk of complications.”

Article complet disponible chez Elsevier.

“A single injection of Durolane is non-inferior to 5 injections of Artz over 18 and 26 weeks for pain, physical function, global self-assessment, and knee stiffness. Both treatments were efficacious, safe, and well tolerated.”

Article complet disponible sur PubMed.gov

“In conclusion, our study supports the use of the NASHA class of products in the treatment of knee OA and found a slight improvement in the economic impact on the healthcare system.”

Article complet disponible sur PubMed.gov

“We conclude that intra-articular hyaluronic acid is a useful intervention in patients with mild to moderate osteoarthritis of the knee, can produce sustained pain relief at 6 months, and can reduce the requirement for analgesia and anti-inflammatory medication during this time.”

Article complet disponible sur Journal of Arthritis

“Factors like a lower age of the patient and the involvement of a single joint influenced the referral of the patient to surgery. The administration of viscosupplementation delayed the time until the patient was finally referred to surgery.”

Article complet disponible à Reumatologíca Cliníca.

“No safety concerns were raised in either the primary study or in the study extension. NASHA as an intra-articular therapyfor osteoarthritis of the knee appears to have an acceptable safety profile and thus merits further investigation regarding its long-term clinical efficacy.”

Résumé de l’article disponible sur SpringerLink

“Our results show that a single intra-articular injection of NASHA is a well tolerated and potentially effective therapy in the treatment of hip OA. Further studies of NASHA in this setting are warranted.”

Résumé de l’article disponible sur PubMed.gov.

“Viscosupplementation of the hip with NASHA is easily feasible in daily clinical practice, safe and well tolerated despite a frequent increase of pain the days following injection. Prospective controlled trials are needed to confirm these data and to evaluate both safety and efficacy of a second course of treatment.”

Résumé de l’article disponible sur PubMed.gov.

“We conclude that a single-injection of Durolane can reduce arthrosis associated knee pain sufficiently. Our data are comparable with those published in clinical studies using other hyaluronic acids. The effects of Durolane are delayed but more sustained compared to those found for glucocorticoids. Because of the single-injection, we see an advantage in using Durolane compared to other conventional hyaluronic acids and glucocorticoids.”

Résumé de l’article disponible sur PubMed.gov.

“The elimination kinetics of 131I-labelled NASHA from the human knee joint were described by three distinct phases, with half-times of 1.5 hours, 1.5 days and 4 weeks. Most likely, the last value reflects the true half-life of NASHA following intra-articular injection since the labelling method used causes minimal modification of hyaluronan.”

Article complet disponible sur PubMed.gov

“This study suggests that viscosupplementation using NASHA is effective and well tolerated in treating the symptoms of rhizarthrosis.”

Article complet disponible sur PubMed.gov

“In conclusion, the results of this prospective cohort study suggest that viscosupplementation with NASHA in the treatment of ankle OA holds promise. A single injection was associated with clinically meaningful reductions in pain and disability for up to 26 weeks and, although 1 participant reported pain and withdrew from the study, the procedure was generally well tolerated. Further investigation of NASHA for the treatment of ankle OA, including a large prospective cohort study and a randomized controlled trial, appear to be merited.”

Article complet disponible sur Journal of Foot & Ankle Surgery